Jerome

see http://www.dividendes.ch/a-propos/

Astrazeneca (NYSE:AZN)

/ / Analysis / 4 Comments

AstraZeneca, the pharmaceutical giant born from the merger of Astra AB and Zeneca PLC, has established itself as one of the world leaders in the sector with around 100,000 employees dedicated to the research, development and marketing of pharmaceutical products. The group presents solid financial indicators, with an attractive yield and a generous dividend distribution policy, although investors should be cautious due to the relative youth of its successive dividend increases.

Astrazeneca (NYSE:AZN) Read More »

New on the site

/ / Unclassified / 11 Comments

  To thank my readers for their loyalty, I have added a new page of information on the stocks followed in the Global Dividend Growers strategy portfolio. By clicking on the name of the stock, for example Colgate-Palmolive, you are taken to the "Stock Details" page which gives you detailed and up-to-date information

New on the site Read More »

Praxair (NYSE:PX)

/ / Analysis / Leave a Comment

Discover Praxair Inc (NYSE:PX), a leading North and South American supplier of industrial gases, distinguished by its global presence and impressive patent portfolio. Despite solid stock performance and stable dividend growth, its current valuation suggests a holding strategy for existing investors rather than a new buying opportunity.

Praxair (NYSE:PX) Read More »

Johnson & Johnson (NYSE:JNJ)

/ / Analysis / 1 Comment

Johnson & Johnson, an American healthcare giant founded in 1886, is one of the world's largest manufacturers of pharmaceutical, medical and cosmetic products with iconic brands such as Tylenol, Band-Aid and Neutrogena. The company stands out for its impressive history of growing dividends for decades, offering attractive stability for investors despite a slightly high payout ratio.

Johnson & Johnson (NYSE:JNJ) Read More »

Dividends: to be or not to be? (episode 3)

/ / Dividends & Stock Market / 5 Comments

An in-depth analysis of different investment strategies, comparing the price action approach advocated by the Very Particular Investor with the dividend-based approach. The article explores in particular the case of Apple (AAPL) and demonstrates how these two approaches can actually be complementary rather than opposed to optimize its stock market returns.

Dividends: to be or not to be? (episode 3) Read More »